Medidata Expands Partnership with CytomX Therapeutics to Centralize Management of Regulated and Nonregulated Content

December 5, 2017

New Agreement Includes Medidata RCM and eTMF Archive for End-to-End Inspection Readiness and Collaboration

NEW YORK--(BUSINESS WIRE)--Dec. 5, 2017-- Medidata (NASDAQ:MDSO), the leading global provider of cloud-based technology and data analytics for clinical research, today announced that CytomX Therapeutics, Inc., a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will expand its partnership to include Medidata Regulated Content Management (RCM) solutions, eTMF Archive and SOP Management.

With the addition of Medidata RCM, CytomX will now manage regulated and nonregulated content in a single, unified platform. Accessible through the Medidata Clinical Cloud®, CytomX will integrate standard operating procedure (SOP) management and electronic trial master file (eTMF) archive to manage all content, data and workflows.

CytomX is also currently using Medidata Rave®, the world's leading solution for capturing, managing and reporting patient data and Medidata Balance®, randomization and trial supply management (RTSM) application, for its oncology research studies.

"We've created a seamless offering with the Medidata platform that can facilitate everything during clinical research, from data collection and management to compliance," said Mike Capone, chief operating officer at Medidata. "Medidata's industry difference is that we enable our customers to take control of their data, helping them meet regulatory requirements and ensure efficient clinical trials."

About Medidata

Medidata is reinventing global drug and medical device development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 950 global pharmaceutical companies, biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.

The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 18 of the world's top 25 global pharmaceutical companies and is used by 18 of the top 25 medical device developers—from study design and planning through execution, management and reporting.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171205005922/en/

Source: Medidata

Medidata Solutions
Investors:
Betsy Frank, +1 917-522-4620
bfrank@mdsol.com
or
Anthony D'Amico, +1 732-767-4331
adamico@mdsol.com
or
Media:
Erik Snider, +1 646-362-2997
esnider@mdsol.com